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OBJECTIVE — Weight loss in patients with type 2 diabetes can improve glycemic control,
lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor ago-
nistsareassociatedwithweightlossandhavepotentiallybeneﬁcialeffectsoncardiovascularrisk
biomarkers; however, there is limited information to indicate whether these effects remain
outside of clinical trials.
RESEARCH DESIGN AND METHODS — Medical records from the General Electric
Centricity research database were analyzed retrospectively to evaluate the relationship between
weight loss and glycemic control and changes in blood pressure and lipids in patients with type
2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90–
365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure,
triglycerides, and LDL, HDL, and total cholesterol were assessed.
RESULTS — A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or
insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean  SD
of 3.0  7.33 kg, sitagliptin-treated patients lost 1.1  5.39 kg, and insulin-treated patients
gained0.69.49kg.Therewasasigniﬁcantassociationbetweenweightlossandareductionin
A1CandFBGwithexenatideonlyandareductioninbloodpressureforalltherapies.Weightloss
wasassociatedwithsomeimprovementsinlipids,primarilyintheGLP-1receptoragonistgroup,
with little association in the insulin group.
CONCLUSIONS — Weight reduction with GLP-1 receptor agonists was associated with a
shifttowardamorefavorablecardiovascularriskproﬁle.Outcometrialsareneededtodetermine
whether improvement in biomarkers translates into a reduction in cardiovascular events in
patients with type 2 diabetes.
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T
he prevalence of type 2 diabetes
continues to increase as does the
number of obese individuals in the
U.S. (1). There is a strong correlation be-
tween the two, with 80–95% of patients
with type 2 diabetes being overweight or
obese.Infact,studieshaveshownthatthe
risk of developing diabetes increases in
proportion to BMI (2). In addition, obe-
sity exacerbates the metabolic abnormal-
ities of type 2 diabetes, in particular,
hyperglycemia, dyslipidemia, and hyper-
tension (3). Obese individuals are at
higher risk of developing cardiovascular
disease, and the risk is even higher in those
with type 2 diabetes who are obese (4).
In overweight and obese individuals
with type 2 diabetes, weight loss is asso-
ciated with improvements in risk factors.
In fact, small amounts of weight loss
(5%) can improve glycemic control in
type2diabetes(5,6).Longitudinalcohort
studies indicate that changes in BMI in
patients with type 2 diabetes are signiﬁ-
cant predictors of changes in A1C and
blood pressure (7), and patients who lose
weight are more likely to achieve goal
A1Candbloodpressurevaluesthanthose
who show stable weight or weight gain
(8). Similarly, lifestyle intervention trials
in patients with type 2 diabetes have
shown that weight loss improves glyce-
mic control, reduces blood pressure, and
improveslipidlevels(9),andevenamod-
est weight loss can result in an improved
cardiovascular risk proﬁle (10). In pa-
tients with type 2 diabetes, intentional
weight loss has been associated with a
28% reduction in cardiovascular disease
and diabetes-related mortality (6). In ad-
dition, weight loss is associated with re-
duced diabetes-related health care costs
(11).
Proper diet and exercise is the ﬁrst-
line therapy to promote weight loss and
improve glycemia in new-onset diabetes,
butmostpatientswillrequireoralantidia-
betes drugs (OADs) for glycemic control
and many will eventually require insulin
therapy. Although these therapies are ef-
fective in lowering A1C, most therapies
lead to weight gain. Sulfonylureas, thia-
zolidinediones, and insulin result in
weight gain of 2 kg for every 1% de-
crease in A1C (12,13). Metformin, unlike
other standard OADs, is often associated
with slight weight loss.
Incretin-based therapies, including
glucagon-like peptide (GLP-1) receptor
agonists and dipeptidyl peptidase-4
(DPP-4) inhibitors, have recently become
treatment options for type 2 diabetes
management, and unlike many other
therapies, they do not induce weight gain
(14). Therapy with GLP-1 receptor ago-
nists results in weight loss in most pa-
tients. In controlled clinical trials, the
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generally sustained or progressive with
long-term therapy (15). These agents
have a physiological effect similar to that
of native GLP-1, including enhancement
of glucose-dependent insulin secretion
and suppression of inappropriately high
glucagon secretion. At high concentra-
tions they also slow gastric emptying and
reduce food intake (16).
By blocking DPP-4, an enzyme that
breaks down GLP-1, DPP-4 inhibitors
have actions similar to that of GLP-1 re-
ceptor agonists; they also enhance glu-
cose-dependent insulin secretion and
suppress glucagon, but they do not delay
gastricemptyingorreducefoodintake.In
controlled clinical trials the effect of sita-
gliptin on weight was neutral (17,18).
Data from clinical trials with ex-
enatide, a GLP-1 receptor agonist, sug-
gest that it has potentially beneﬁcial
effects on biomarkers of cardiovascular
risk in patients with type 2 diabetes, in-
cluding lowering blood pressure and
improving dyslipidemia (19). However,
there is limited information as to
whether these effects remain outside of
the setting of controlled clinical trials.
In addition, it is not clear whether the
effects on blood pressure and lipids are
due to the weight loss that occurs with
GLP-1 receptor agonists. Therefore, we
evaluated patients with type 2 diabetes
who initiated an incretin-based (GLP-1
receptor agonist or DPP-4 inhibitor) or
insulin-basedregimentoanalyzethere-
lationship between weight change and
glycemic control and improvement in
cardiovascularriskbiomarkersinareal-
world setting.
RESEARCH DESIGN AND
METHODS— Aretrospectiveanalysis
of outpatient electronic medical records
(EMR)obtainedfromtheGeneralElectric
Centricity research database was con-
ducted. This research database contains
information on 540,000 patients with
type 2 diabetes from 49 states between
January 1996 and January 2008.
Included in the analysis were adult
patients (18 years) with a diagnosis of
type 2 diabetes (based on ICD-9 codes),
who received prescription orders for ex-
enatide,sitagliptin,orinsulinonorafter1
January 2005. The ﬁrst observed pre-
scription deﬁned the index date. Patients
were to have a treatment duration of 60
days and no use of a comparator regimen
within 3 months before and 12 months
after the index date. Patients were in-
cluded if they had 90 days of activity in
the EMR database before and after the in-
dex date.
Outcome measures
Patient records were examined for body
weight and at least one of the following
outcomes: A1C, fasting blood glucose
(FBG), systolic blood pressure (SBP), di-
astolic blood pressure (DBP), triglycer-
ides, LDL cholesterol, HDL cholesterol,
and total cholesterol. The baseline mea-
surement was observed within 60 days
beforeto30daysaftertheindexdate.The
follow-upmeasurementwasobservedbe-
tween 90 and 365 days after the index
date. Patients without a baseline and fol-
low-up measurement for at least one of
the noted outcome measures were ex-
cluded from the study.
Statistical methods
Foreachtreatmentgroup,outcomeswere
stratiﬁed by various levels of weight
change observed from baseline to follow-
up. Analyses were performed only for pa-
tients with both baseline and follow-up
valuesforaspeciﬁcoutcomeparameterof
interest. The statistical signiﬁcance of de-
scriptivedifferencesinoutcomesbetween
weight change groups was measured us-
ing ANOVA for continuous measures and

2 tests for categorical measures. Multi-
variateregressionswereestimatedtocon-
trol for confounders among patients in
various weight change categories. Linear
regression was implemented to assess the
effect of weight change on continuous
outcomes. Logistic regression models
were estimated to evaluate the effect of
each level of weight change on dichoto-
mous outcomes and are reported as odds
ratios, which show the increased or de-
creased likelihood of the dichotomous
outcome being true for patients in each
weight change category relative to indi-
viduals with no weight loss (i.e., no
weight change or weight gain). In addi-
tion to the weight loss categories, covari-
ates included age, sex, baseline weight,
geographic region, payer type, Charlson
Comorbidity Index, number of days be-
tween baseline and follow-up observa-
tion, baseline use of other OADs, and
baseline value of the outcome variable
modeled. Analyses were conducted us-
ing SAS (version 9; SAS Institute, Cary,
NC).
RESULTS— A total of 6,280, 5,861,
and 32,398 patients receiving exenatide,
sitagliptin, or, insulin, respectively, met
Table1—Patientdemographicsandbaselinecharacteristicsobservedwithin60daysbeforeto
30 days after the index date
Parameter Exenatide Sitagliptin Insulin
n 6,280 5,861 32,398
Age (years) 57  11.0 62  11.8 61  13.7
Sex (% female) 59 49 52
BMI (kg/m
2) 38.5  7.94 33.8  7.51 33.6  8.29
Weight (kg) 110  24.7 97  23.4 96  25.0
Charlson score 0.52  1.08 0.74  1.29 0.63  1.26
Medications (%)
Antihypertensive drug(s) 54 54 71
Lipid-lowering drug 50 49 55
Sulfonylurea 24 22 15
Metformin 44 40 20
Thiazolidinediones 23 22 13
No other OADs 41 42 66
1 other OAD 33 36 21
2 other OADs 20 18 11
3 other OADs 6 5 3
4 other OADs 1 1 1
Payer type (%)
Commercial 48 40 29
Medicaid 1 13
Medicare 17 30 30
Self 1 11
Unknown 33 29 38
Data are means  SD unless otherwise indicated.
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graphics of these patients are shown in
Table 1. Baseline and follow-up values of
the cardiovascular risk biomarkers as-
sessed are shown in Table 2. Patients in
theinsulingrouphadsubstantiallyhigher
A1C and FBG at baseline than those re-
ceiving exenatide or sitagliptin.
Weight change
Exenatide-treated patients lost a mean 
SD of 3.0  7.33 kg (P  0.0001), sita-
gliptin-treated patients lost 1.1 5.39 kg
(P  0.009), and patients receiving insu-
lin gained 0.6  9.49 kg (P  0.002)
during the follow-up period. More ex-
enatide-treated patients lost 5% of their
body weight, and more insulin-treated
patientsgained5%oftheirbodyweight
(Table 3, supplementary Fig. 1, available
in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc09-2062/DC1). The number of days
from the baseline to the follow-up weight
assessment was 270  85.7 in the ex-
enatidegroup,21683.7inthesitaglip-
tin group, and 266  87.6 in the insulin
group.
Glycemic control
Glycemic control improved in all treat-
ment groups, with reductions in A1C of
0.5  1.4, 0.6  1.4, and 1  2.2% and
in FBG of 9.9  58.7, 13.5  63.8, and
25.3102.8mg/dlintheexenatide,sita-
gliptin, and insulin groups, respectively.
Changes in body weight were signiﬁ-
cantly associated with reductions in A1C
(P0.0001foralltreatmentgroups)and
reductionsinFBG(P0.002,P0.008,
and P  0.0001 for exenatide, sitagliptin,
andinsulin,respectively)(Table3).How-
ever, for exenatide, a greater change in
A1C and FBG occurred in those with
weightlossandforsitagliptinandinsulin,
greater reductions occurred in those with
weight gain.
Blood pressure
Both SBP and DBP were reduced from
baseline at follow-up, with reductions of
2.3  17.6 and 1.2  10.8 mm Hg, re-
spectively, for exenatide, 1.1  18.2 and
0.6  10.8 mm Hg for sitagliptin, and
1.8  21.3 and 1.3  12.5 mm Hg for
insulin. Weight loss was signiﬁcantly as-
sociated with reductions in both SBP and
DBP in all treatment groups (P  0.0001
for each) (Table 3).
Lipid parameters
In all three treatment groups, there was a
trend toward improvement in lipid pa-
rameters from baseline to follow-up, with
the exception of HDL, which remained
essentially unchanged. Reductions in
lipidparametersintheexenatide,sitaglip-
tin,andinsulingroups,respectively,were
as follows: triglycerides, 27  149.9,
20  128.9, and 45  225.8 mg/dl; LDL
cholesterol, 4  33.4, 6  32.0, and 8 
37.7 mg/dl; HDL cholesterol, 0.5  7.0,
0.7  7.4, and 0.2  9.9 mg/dl; and total
cholesterol, 11  40.3, 10  40.0, and
14  48.5 mg/dl. In patients initiating
exenatide, change in weight was signiﬁ-
cantly associated with improvements in
triglycerides(P0.007),LDLcholesterol
(P  0.005), and total cholesterol (P 
0.001). In patients initiating sitagliptin,
change in weight was signiﬁcantly associ-
ated with improvements in triglycerides
(P  0.001) and total cholesterol (P 
0.001). In patients initiating insulin,
change in weight was signiﬁcantly associ-
atedonlywithimprovementsintotalcho-
lesterol (P  0.02) (Table 3).
Table 2—Baseline and follow-up glycemic and lipid parameters
Parameter Exenatide Sitagliptin Insulin
n 6,280 5,861 32,398
A1C
At baseline (%) 7.7  1.54 7.7  1.53 8.8  2.28
At follow-up (%) 7.2  1.39 7.2  1.25 7.8  1.80
% with baseline and follow-up 62 60 44
Days between baseline and follow-up 258  82.3 209  80.5 253  83.9
FBG
At baseline (mg/dL) 157  58.4 159  61.2 187  91.0
At follow-up (mg/dL) 144  51.4 145  50.9 160  76.2
% with baseline and follow-up 39 41 32
Days between baseline and follow-up 258  84.5 213  80.9 258  86.4
SBP
At baseline (mmHg) 130  16.1 130  17.1 132  19.7
At follow-up (mmHg) 128  15.0 129  16.0 130  18.7
% with baseline and follow-up 100 99 99
Days between baseline and follow-up 272  85.7 218  83.9 269  87.6
DBP
At baseline (mmHg) 77  10.0 76  10.5 75  11.8
At follow-up (mmHg) 76  9.3 75  10.2 74  11.3
% with baseline and follow-up 99 99 99
Days between baseline and follow-up 272  85.9 218  83.8 269  87.6
Triglycerides
At baseline (mg/dL) 209  166.9 188  166.3 223  248.3
At follow-up (mg/dL) 183  145.3 162  115.0 185  184.8
% with baseline and follow-up 27 24 18
Days between baseline and follow-up 253  81.4 211  79.6 247  83.3
LDL cholesterol
At baseline (mg/dL) 95  35.8 96  35.7 100  40.4
At follow-up (mg/dL) 91  33.1 91  33.0 94  36.2
% with baseline and follow-up 32 25 18
Days between baseline and follow-up 250  82.8 210  80.5 245  84.0
HDL cholesterol
At baseline (mg/dL) 43  11.6 44  12.4 45  14.3
At follow-up (mg/dL) 43  11.3 44  12.1 45  13.9
% with baseline and follow-up 39 34 25
Days between baseline and follow-up 252  82.4 209  79.9 246  84.1
Total cholesterol
At baseline (mg/dL) 177  45.7 175  44.7 183  53.0
At follow-up (mg/dL) 166  40.7 166  40.2 171  46.5
% with baseline and follow-up 38 34 25
Days between baseline and follow-up 252  82.3 207  78.7 246  84.2
DataaremeansSDunlessotherwiseindicated.ConversationfactorsforSIunits(millimolesperliter):FBG,
0.05551; HDL cholesterol, LDL cholesterol, and total cholesterol, 0.02586; triglycerides, 0.0113.
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Results of the multivariate regression
analyses evaluating the effect of weight
loss on the change in outcome variables
relative to patients who did not lose
weight or those who gained weight are
shown in Fig. 1. After we controlled for
baseline confounding factors including
baseline weight, there was a clear beneﬁt
on A1C and FBG from any weight loss in
exenatide-treatedpatients,butthebeneﬁt
on A1C in sitagliptin- or insulin-treated
patients was seen only in patients losing
8% body weight (Fig. 1A and B). Pa-
tients with weight loss of at least 3–5%
were more likely to have reductions in
SBP and DBP in all treatment groups
(Fig. 1C and D). Patients with weight
loss of 5% while receiving incretin-
based therapies were more likely to
have reductions in triglycerides, total
cholesterol, and LDL cholesterol levels
(Fig. 1E–G). There appeared to be min-
imal association of weight loss and an
increase in HDL cholesterol levels in all
treatment groups (Fig. 1H).
CONCLUSIONS— We evaluated the
impact of weight loss on glycemic control
and improvements in biomarkers of car-
diovascular risk in patients with type 2
diabetesinitiatingtreatmentwithaGLP-1
receptor agonist, a DPP-4 inhibitor, or in-
sulin, three classes of drugs with different
effects on weight (weight loss, weight
neutral, and weight gain, respectively), in
a real-world setting using a large cohort
database. Patients initiating a GLP-1 re-
ceptor agonist and a DPP-4 inhibitor had
signiﬁcant weight loss from baseline and
patients initiating insulin had signiﬁcant
weight gain. Signiﬁcant incremental ben-
eﬁts in glycemic control were associated
with weight loss in patients receiving a
GLP-1 receptor agonist, but this associa-
tion was only seen with weight loss of
8% with a DPP-4 inhibitor or insulin.
Small amounts of weight loss were asso-
ciated with reduction in SBP in all treat-
ment groups, and larger amounts of
weight loss were associated with reduc-
tions in DBP. Weight loss in patients ini-
tiating incretin-based therapies was
associated with some improvements in
Table 3—Percentage of patients with weight change by category and mean change in glycemic and lipid parameters based on the speciﬁed
weight change category*
Parameter Lost 5% Lost 3–4% Lost 1–2% No change Gained 1–2% Gained 3–4% Gained 5% P value†
Body weight change (%)
Exenatide 32.7 15.1 17.3 9.0 12.4 6.6 6.8 NA
Sitagliptin 18.7 14.0 20.4 10.9 18.0 9.0 9.0 NA
Insulin 17.0 9.0 13.5 8.0 15.9 12.4 24.2 NA
A1C (%)
Exenatide 0.7 0.5 0.3 0.3 0.3 0.3 0.7 0.0001
Sitagliptin 0.7 0.5 0.4 0.5 0.6 0.6 1.1 0.0001
Insulin 0.8 0.5 0.6 0.6 0.7 0.9 1.7 0.0001
FBG (mg/dL)
Exenatide 16.6 10.3 5.9 1.9 2.4 8.7 11.0 0.002
Sitagliptin 19.6 8.3 8.3 8.4 13.1 15.1 23.7 0.008
Insulin 18.2 12.7 15.0 18.8 23.7 25.7 43.0 0.0001
SBP (mmHg)
Exenatide 5.0 3.0 0.9 0.1 0.0 0.4 0.3 0.0001
Sitagliptin 3.9 2.2 1.1 1.2 0.9 0.9 2.3 0.0001
Insulin 5.6 3.3 2.1 1.5 1.6 0.2 0.6 0.0001
DBP (mmHg)
Exenatide 2.4 1.1 0.5 0.8 0.3 0.9 0.4 0.0001
Sitagliptin 1.8 0.6 0.6 0.5 0.2 0.6 0.3 0.0004
Insulin 2.7 1.9 1.2 1.0 1.2 0.8 0.5 0.0001
Triglycerides (mg/dL)
Exenatide 43.4 25.2 11.6 6.4 28.0 29.6 3.5 0.007
Sitagliptin 45.6 35.2 17.5 8.1 1.7 7.8 11.8 0.001
Insulin 51.4 37.2 36.8 44.4 34.8 49.5 50.3 0.49
Total cholesterol (mg/dL)
Exenatide 16.4 9.2 8.8 9.0 8.0 6.6 4.7 0.0003
Sitagliptin 14.5 14.8 6.0 5.6 4.7 12.9 13.5 0.0005
Insulin 14.2 17.8 12.4 12.5 12.7 11.7 16.6 0.02
LDL-cholesterol (mg/dL)
Exenatide 8.1 0.2 1.4 3.1 1.4 2.7 4.0 0.005
Sitagliptin 7.3 9.8 4.7 2.2 4.1 8.4 7.9 0.24
Insulin 7.7 10.7 8.9 6.7 7.3 6.5 9.5 0.30
HDL-cholesterol (mg/dL)
Exenatide 0.9 0.6 0.3 0.3 0.5 0.7 1.1 0.06
Sitagliptin 0.3 1.1 0.6 1.4 0.7 0.4 0.9 0.63
Insulin 0.1 0.4 0.2 0.4 0.8 0.1 0.3 0.09
*Percentages were rounded to whole numbers. Actual ranges were 0.5–0.5% of listed ranges. †Cross-category ANOVA. NA, not applicable.
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not losing weight: a reduction in triglyc-
erides, LDL cholesterol, and total choles-
terol with the GLP-1 receptor agonist and
a reduction in triglycerides and total cho-
lesterol with the DPP-4 inhibitor. There
was no clear association between weight
loss and improvement in lipid proﬁles
with insulin.
The beneﬁt of the weight loss with
GLP-1 receptor agonists has been shown
in other studies. In a 2-year open exten-
sion trial of exenatide in 283 patients
stratiﬁedbyweightchangequartile,those
with the greatest weight loss had the
greatest improvement in A1C (15). In an
82-week, open-label extension trial of
exenatide in 314 patients, signiﬁcant
improvements in HDL cholesterol, tri-
glycerides, and DBP were seen with
trends for improvement in total choles-
terol,LDLcholesterol,andSBP.Whenas-
sessed by weight change quartile, those
losing the most weight had the greatest
improvements in SBP, DBP, HDL choles-
terol, and triglycerides (20). In 151 pa-
tients followed in open-label extension
trials of exenatide for 3.5 years and strat-
iﬁed by weight change quartile, those los-
ing the most weight had the greatest
improvements in triglycerides, HDL cho-
lesterol, and blood pressure. However,
overall there was minimal correlation be-
tween weight loss and changes in lipid
levels(19).Recently,ina1-yearextension
trial of exenatide once weekly, weight
change was shown to be signiﬁcantly cor-
related with reductions in DBP, LDL cho-
lesterol,andtotalcholesterolbutnotwith
triglycerides and SBP (21).
It is clear from these various studies
that the weight loss associated with a
GLP-1 receptor agonist provides beneﬁ-
cial effects on glycemic control and bi-
omarkers of cardiovascular risk. The
reasons for the differences in the biomar-
kers that improved in the various studies
are speculative, but the differences may
be due to the size of the population eval-
uated and the type of analysis. The
present study was a retrospective analysis
of data obtained from EMR; therefore, al-
though the known variables were ad-
justed for in the regression analyses,
unidentiﬁed factors may have con-
founded outcome measures. Only pa-
tients with baseline and follow-up levels
of the various outcome parameters were
included in each analysis, which may
haveincludedpatientswhoinherentlyre-
quired more monitoring and were not
necessarilyrepresentativeoftheentirepa-
Figure1—Oddsratioand95%CIoftheassociationofweightloss(percentagefrombaseline)with
anyreductionin(A)A1C,(B)FBG,(C)SBP,(D)DBP,(E)triglycerides,(F)totalcholesterol,or
(G) LDL cholesterol and (H) increases in HDL cholesterol relative to no weight loss after adjust-
ment for covariates.*P  0.05, **P  0.0001, compared with patients who did not lose weight.
Orange, exenatide; green, sitagliptin; red, insulin.
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ysis provides insight into outcomes that
occur in the clinical setting with a large
number of patients and provides valuable
“real-world” information.
Of the three therapies evaluated in
this analysis, exenatide exhibited the
strongestweightbeneﬁt,followedbysita-
gliptin. To further evaluate the contribu-
tions of weight loss, a regression analysis
of the impact of weight loss for each out-
comeparametercombiningallthreetreat-
ment groups was performed post hoc
(data not shown). There remained a sig-
niﬁcant weight effect for most of the out-
come parameters independent of the
treatment, suggesting the important ben-
eﬁts of weight loss in patients with type 2
diabetes. Furthermore, because the
weight loss associated with GLP-1 ago-
nists provided more improvement in car-
diovascular biomarkers than a DPP-4
inhibitor, this may provide some insight
into the amount of weight loss needed to
achieveclinicalbeneﬁt.Inaddition,phar-
macological GLP-1 levels may have a
weight-independent beneﬁcial effect.
Retrospective analyses from large
EMR databases provide insight into the
effectiveness of drugs when used in clini-
cal practice encompassing all types of pa-
tients. In addition, data from a large
number of patients can be obtained, sam-
plesizesthatcannotbeeasilyobtainedfor
prospective clinical trials. However, the
retrospective nature of database analyses
does have limitations. To capture a large
patient sample, baseline values could be
obtained 60 days before or 30 days after
the index date, and follow-up values
could range from 90 to 365 days after the
index date. Therefore, there is a potential
for inadequate follow-up times to assess
outcomes, particularly change in weight,
the key parameter on which the analyses
were based. However, the mean number
of days of follow-up for weight in each
group (270, 216, and 266 for exenatide,
sitagliptin, and insulin, respectively) was
adequate for assessment of outcomes.
Similarly, the interval between baseline
and follow-up assessments of other out-
come parameters was 8 months. An-
other limitation to the use of EMR
databases is the inability to assess adher-
ence to and persistence with the pre-
scribed therapy as well as changes in
adherence to and persistence with con-
comitant OADs. Because some patients
were receiving sulfonylureas and thia-
zolidinediones, which can cause weight
gain, stopping them during the follow-up
period could have affected change in
weight. Large database analyses are also
subject to the variability induced by gly-
cemicandlipidvaluesmeasuredatdiffer-
ent laboratories.
Treatment of type 2 diabetes is mul-
tifactorial, including not only glycemic
control but also control of cardiovascular
risk factors. Ideal therapies may be those
thatachievemorethanonetarget,includ-
ing blood pressure and lipids, as well as
A1C, without gain in body weight.
Weight reductions with incretin-based
therapies, and, in particular, GLP-1 re-
ceptor agonists for which greater weight
loss was seen, were associated with shifts
toward a more favorable cardiovascular
risk proﬁle. Further research is needed to
determine whether these changes trans-
late into a reduction in cardiovascular
events.
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